HT PARP in Vivo Pharmacodynamic Assay II

Gaithersburg, MD, February 02, 2010 --(PR.com)-- Pharmacodynamic (PD) assays have recently been developed and employed early in the drug screening process to assess the ability of potential drug candidates to affect molecular targets. These assays have the advantages of performing molecular proof-of-concept investigations at an early stage such as phase 0 trials, and later can be used to stratify patients into treatment pools during any stage of clinical assessment.

In cancer drug development, a current molecular target of high interest is poly(ADP-ribose) polymerase (PARP), as it is intimately involved in DNA repair and the survival or death of cancer cells. Until now, measuring the effectiveness of PARP inhibitors in cell and tissue lysates has been difficult and time consuming due to a lack of refined immunological reagents in an optimized and quantitative assay. Traditional PARP assays require the transfection of damaged DNA into the cells of interest in order to measure endogenous PARP activity, an especially difficult step when assaying cells from tissues.

Trevigen addresses this problem with the release of the HT PARP in vivo Pharmacodynamic Assay II, which is a high throughput, Chemiluminescent, PAR ELISA assay kit that has been validated on human peripheral blood lymphocytes and also shown to work with normal and tumor tissue. This improved assay features:

· Pre-coated capture antibody plates.
· Broad linear dynamic range to 1,000 pg/ml.
· High signal to noise ratio.
· Detection sensitivity of 2 pg/ml of PAR.

The amount of PAR present correlates directly with the activity of the PARP enzyme in cell lysates. This assay is ideal for quantification of PAR in peripheral blood mononuclear cells, tissues and cultured cells.

Related Products from Trevigen include PARP and PARG assay and cellular differentiation kits, PARP enzymes and PARP antibodies. Visit www.trevigen.com or contact us at 1-800-873-8443 or info@trevigen.com for more information.

###